News Releases

Date Title  
09/10/18
Summary TogglePLx Pharma Inc. to Present at Janney Healthcare Conference on September 18

HOUSTON , Sept. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today
PDF Version
08/10/18
Summary TogglePLx Pharma Inc. Reports Second Quarter 2018 Results

Announces that FDA has approved new name Vazalore for PLx’s next generation, novel aspirin HOUSTON , Aug. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products,
PDF Version
06/11/18
Summary TogglePLx Pharma Inc. to Present at JMP Securities Life Sciences Conference

HOUSTON , June 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
05/11/18
Summary TogglePLx Pharma Inc. Reports First Quarter 2018 Results

HOUSTON , May 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
03/23/18
Summary TogglePLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
HOUSTON , March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
03/15/18
Summary TogglePLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call
HOUSTON , March 15, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
11/09/17
Summary TogglePLx Pharma Inc. Reports Third Quarter 2017 Results
HOUSTON , Nov. 09, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today its
PDF Version
11/02/17
Summary TogglePLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
HOUSTON , Nov. 02, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
09/19/17
Summary TogglePLx Pharma Hires Key Commercial Executives in Preparation for Future Launch of Aspertec
Industry Veterans Will Support Manufacturing and Trade Sales HOUSTON , Sept. 19, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81
PDF Version
09/18/17
Summary TogglePLx Pharma Present at the Sidoti & Company Fall 2017 Conference
HOUSTON , Sept. 18, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
Displaying 1 - 10 of 23 results